

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

Information for the public
Published: 3 August 2022

www.nice.org.uk

Abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are available on the NHS. They are possible treatments for severe atopic dermatitis (eczema) in adults and young people 12 years and over, if at least 1 systemic immunosuppressant has not worked well enough, or systemic immunosuppressants are not suitable.

Tralokinumab (Adtralza) is available on the NHS. It is a possible treatment for severe atopic dermatitis in adults, if at least 1 systemic immunosuppressant has not worked well enough, or systemic immunosuppressants are not suitable.

Only people whose atopic dermatitis improves enough by 16 weeks can carry on with treatment.

When assessing how dermatitis affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.

If you are not eligible for abrocitinib, upadacitinib or tralokinumab but are already having 1 of them, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Eczema Outreach Support \(EOS\)](#), 01506 840 395
- [National Eczema Society](#), 0800 448 0818

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4707-2